Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Xocova Price to Be Trimmed by 300 Yen after CEA; No Change for Mounjaro
November 14, 2024
- LDP’s Hirobumi Niki Appointed Senior Vice Health Minister
November 14, 2024
- Draft Economic Package Embraces Measures to Ensure Stable Generic Supply
November 13, 2024
- DPP to Ruling Bloc: Quickly Scrap Off-Year Drug Price Revisions
November 13, 2024
- Ex-LDP Bigwig Kamoshita Urges Pharma Industry to Speak Up More
November 13, 2024
- Opposition Party Lawmakers Push for Abolishing Off-Year Price Revisions
November 13, 2024
- MHLW to Expedite Procedures for Public Knowledge-Based Applications
November 12, 2024
- Anapeine Generics Get Expedited Listing amid Supply Crunch
November 12, 2024
- Top MHLW Bureaucrat Hints Party Debate Will Affect Fate of Off-Year Revision
November 11, 2024
- MHLW Eyes Extra Budget for Pharma Innovation, Generic Rejig
November 11, 2024
- MHLW Issues Guidance on Early Approval Scheme for MCMs
November 8, 2024
- Chuikyo Supports Full Rollout of Company Indices for Generics Manufacturers
November 7, 2024
- Chuikyo Doubts Effect of Re-Pricing for Unprofitable Products
November 7, 2024
- Advisory Panel Backs Transfer of GMP Inspection Authority for New Generics to PMDA
November 5, 2024
- PMDA Opens US Office in Washington, D.C.
November 5, 2024
- Pediatric Use of 3 ITP Drugs Near Official Approval in Japan
November 1, 2024
- Govt’s Council Calls for Pushing Drug Innovation, Generic Revamp
October 31, 2024
- BeiGene’s Brukinsa, J&J’s Balversa and More Now in Line for Japan Approval
October 31, 2024
- LDP’s Hashimoto Regrets Election Defeat amid Off-Year Debate
October 30, 2024
- Ruling Bloc’s Loss of Lower House Majority Might Sway Off-Year Revision Debates
October 29, 2024
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…